BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Johnson and Johnson
Dow
Merck
Moodys
Teva
Chubb
Fish and Richardson
US Department of Justice
Healthtrust

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,900,175

« Back to Dashboard

Summary for Patent: 6,900,175
Title: Methods of administering dalbavancin for treatment of bacterial infections
Abstract:The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of dalbavancin for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimes include once weekly administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection.
Inventor(s): Cavaleri; Marco (Saronno, IT), Jabes; Daniela (Cassina Rizzardi, IT), Henkel; Timothy (Berwyn, PA), Malabarba; Adriano (Buccinasco, IT), Mosconi; Giorgio (Malvern, PA), Stogniew; Martin (Blue Bell, PA), White; Richard J. (Emeryville, CA)
Assignee: Vicuron Pharmaceuticals Inc. (King of Prussia, PA)
Application Number:10/714,261
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 6,900,175

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc DALVANCE dalbavancin hydrochloride POWDER;IV (INFUSION) 021883-001 May 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN. ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,900,175

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,115,564 Stable pharmaceutical compositions of dalbavancin and methods of administration ➤ Subscribe
7,119,061 Dalbavancin compositions for treatment of bacterial infections ➤ Subscribe
8,143,212 Dalbavancin compositions for treatment of bacterial infections ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,900,175

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003294262 ➤ Subscribe
Australia 2003298662 ➤ Subscribe
Australia 2003299561 ➤ Subscribe
Australia 2005325261 ➤ Subscribe
Australia 2011200423 ➤ Subscribe
Brazil PI0510269 ➤ Subscribe
Canada 2506236 ➤ Subscribe
Canada 2564112 ➤ Subscribe
China 100339129 ➤ Subscribe
China 101130060 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Cantor Fitzgerald
Boehringer Ingelheim
QuintilesIMS
McKesson
Johnson and Johnson
AstraZeneca
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot